Clinical trial · Interventional
Comparison of Microwave and Radiofrequency Ablation for Liver
A Randomized Controlled Trial of Microwave and Radiofrequency Ablation in the Treatment of Early-stage Hepatocellular Carcinoma Meeting Milan Criteria
NCT02539212CI-TRIAL-00019015completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
According to randomized controlled trial requirement, the therapeutic effectiveness of cooled-probe microwave ablation and radiofrequency ablation on early-stage hepatocellular carcinoma is compared to find a better approach for minimally invasive thermal ablation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| microwave ablation | Device | — | UNRESOLVED |
| radiofrequency ablation | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- microwave ablation
- description
- microwave ablation
- interventionNames
- Device: microwave ablation
- type
- ACTIVE_COMPARATOR
- label
- radiofrequency ablation
- description
- radiofrequency ablation
- interventionNames
- Device: radiofrequency ablation
Primary outcomes (1)
- measure
- Cumulative survival rates were calculated by the Kaplan-Meier method, and comparison between MWA and RFA was done by the log-rank test.
- timeFrame
- up to 79 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * tumor size ≤5cm in diameter, * tumor number ≤3, * Child-Pugh class A or B classification, * no evidence of extrahepatic metastasis, * vein or bile duct tumor embolus, and * no any other anti-cancer treatment Exclusion Criteria: * not meeting the inclusion criteria
References
Publications (0)
Data not yet available
No reference posted for this study.